The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

PDL BioPharma Inc

Nasdaq: PDLI
Last

(U.S.) $5.18

Today's change-0.03 -0.58%
Updated September 4 4:00 PM EDT. Delayed by at least 15 minutes.
 

PDL BioPharma Inc

Nasdaq: PDLI
Last

(U.S.) $5.18

Today's change-0.03 -0.58%
Updated September 4 4:00 PM EDT. Delayed by at least 15 minutes.

PDL BioPharma Inc down (U.S.)$0.03

PDL BioPharma Inc closed lower Friday, dropping (U.S.)$0.03 or 0.58% to (U.S.)$5.18. Over the last five days, shares have lost 8.32% and are down 32.81% for the last year to date. This security has underperformed the S&P 500 by 42.66% during the last year.

Key company metrics

  • Open(U.S.) $5.12
  • Previous close(U.S.) $5.21
  • High(U.S.) $5.25
  • Low(U.S.) $5.12
  • Bid / Ask-- / --
  • YTD % change-32.81%
  • Volume1,667,450
  • Average volume (10-day)2,779,739
  • Average volume (1-month)2,463,095
  • Average volume (3-month)2,547,490
  • 52-week range(U.S.) $4.58 to (U.S.) $9.83
  • Beta0.68
  • Trailing P/E2.78×
  • P/E 1 year forward2.39×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend(U.S.) $0.60
  • Dividend yield11.58%
  • Trailing EPS(U.S.) $1.87
Updated September 4 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+56.21%

Based on its net profit margin of 56.21%, PDL BioPharma Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.87%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue138150117165
Total other revenue--------
Total revenue138150117165
Gross profit--------
Total cost of revenue--------
Total operating expense78186
Selling / general / administrative78186
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)0000
Other operating expenses, total--------
Operating income13114299159
Interest income (expense), net non-operating-7-9-9-9
Gain (loss) on sale of assets--------
Other--------
Income before tax12413490150
Income after tax788455102
Income tax, total45493547
Net income788455102
Total adjustments to net income--------
Net income before extra. items788455102
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items788455102
Inc. avail. to common incl. extra. items788455102
Diluted net income788555102
Dilution adjustment--100
Diluted weighted average shares165170197167
Diluted EPS excluding extraordinary itemsvalue per share0.470.500.280.61
Dividends per sharevalue per share0.000.150.150.15
Diluted normalized EPSvalue per share0.470.500.280.61